Immunome
IMNM
35 hedge funds and large institutions have $15.4M invested in Immunome in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 0 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
65% more capital invested
Capital invested by funds: $9.34M → $15.4M (+$6.08M)
19% more call options, than puts
Call options by funds: $312K | Put options by funds: $263K
17% more funds holding
Funds holding: 30 → 35 (+5)
0.73% more ownership
Funds ownership: 15.22% → 15.95% (+0.73%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.29M |
| 2 |
Renaissance Technologies
New York
|
+$85.3K |
| 3 |
Cerity Partners
New York
|
+$75.3K |
| 4 |
HBCM
Heron Bay Capital Management
Bloomfield Hills,
Michigan
|
+$71.9K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$56.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$1.75M |
| 2 |
Millennium Management
New York
|
-$457K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.1K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$5.47K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$820 |
IMNM Hedge Fund Activity: Q2 2023 in Review
35 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2023, worth a combined $15.4M — up 65% from $9.34M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMNM positions and 0 closed out — a net gain of 5 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.29M. The largest seller was Prentice Capital Management, cutting an estimated $1.75M.
- 35 institutional investors held Immunome (IMNM) as of Q2 2023, up from 30 in Q1 2023.
- Funds reported $15.4M of Immunome stock for Q2 2023, up 65% quarter-over-quarter.
- 5 funds opened new Immunome positions in Q2 2023 and 0 closed out, a net change of +5 holders.
- The largest Immunome buyer in Q2 2023 was Point72 Asset Management, an estimated $2.29M added.
- The largest Immunome seller in Q2 2023 was Prentice Capital Management, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2023.